It was reported on Monday that the US Food and Drug Administration (USFDA) has granted approval to Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical Industries Limited, for its Cassipa sublingual film as a maintenance treatment for opioid dependence.
USFDA has approved new dosage strength (16mg / 4mg) of Cassipa (buprenorphine and naloxone) sublingual film. It is also approved in both brand name and generic versions and various strengths, in combination with counselling and other behavioural therapies to treat patients with opioid use disorder (OUD).
According to USFDA, the product must be used under a complete treatment plan, with up to a dose of 16mg of buprenorphine using another marketed product.
Dr. Reddy's Laboratories unveils Chlorthalidone Tablets, USP in the US market
Perrigo awarded US FDA tentative approval for first to file generic Ultravate Lotion 0.05%
Indivior PLC unveils PERSERIS once-monthly in the US antipsychotic market
Armas Pharmaceuticals to launch Azacitidine for Injection 100 MG in US
Nexus Pharmaceuticals Receives FDA Approval for Arsenic Trioxide Injection in 10mg per 10mL Vial
Nexus Pharmaceuticals introduces Arsenic Trioxide Injection 10mg per 10mL vial in US
Dr. Reddy's Laboratories unveils Atomoxetine Capsules, USP in the US Market
Mayne Pharma acquires US and Australian rights to halobetasol foam 0.05%
Fresenius Kabi Introduces Leukemia Drug Arsenic Trioxide Injection in 10 mg per 10 mL vial
Breckenridge wins final US FDA approval for Clobazam Tablets ANDA
Teva Formalises North America Headquarters Move with Ceremony in Israel
Amneal to unveil generic Isoproterenol Hydrochloride Injection USP in the US